Antares Pharma Inc. (NASDAQ: ATRS) Submits IND for ATRS-1902 Clinical Study In Adrenal Crisis Management

June 29, 2021

Antares Pharma Inc. (NASDAQ: ATRS) has announced an Investigational New Drug Application to the FDA to commence its Phase 1 ATRS-1902 clinical study to treat adrenal crisis rescue.  Adrenal crisis is associated with cortisol deficiency  The ATRS-1902 application and corresponding development program support proposed acute adrenal insufficiency (adrenal crisis) treatment using a new proprietary auto-injector delivery platform for hydrocortisone.  Dr. Peter Richardson, Antares Pharma EVP R&D, and Chief Medical Officer…

Read More >>